Menopause and hormone replacement therapy: An overview

Obstetrics and Gynecology

Volumn 87, Issue 2 II SUPPL., 1996, Pages

  Hammond, Charles B ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; BELLERGAL; CALCITONIN; CALCIUM; CLONIDINE; ESTRADIOL; ESTROGEN; ESTROGEN RECEPTOR; ESTRONE; ETIDRONIC ACID; FLUORIDE; FOLLITROPIN; GESTAGEN; GONADORELIN; LUTEINIZING HORMONE; PROPRANOLOL; TESTOSTERONE;

AGING; AMENORRHEA; BONE ATROPHY; BONE DENSITY; BREAST CANCER; CALCIUM INTAKE; CARDIOVASCULAR DISEASE; CIGARETTE SMOKING; CLIMACTERIUM; CORONARY ARTERY ATHEROSCLEROSIS; DEPRESSION; DIABETES MELLITUS; DOCTOR PATIENT RELATION; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; ESTROGEN THERAPY; FEMALE; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; LONG TERM CARE; MENOPAUSAL SYNDROME; MENOPAUSE; OBESITY; ORAL DRUG ADMINISTRATION; PATHOLOGIC FRACTURE; PATIENT COMPLIANCE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; VAGINA ATROPHY;

EID: 0030045875     PISSN: 00297844     EISSN: None     Source Type: Journal    
DOI: 10.1016/0029-7844(95)00429-7     Document Type: Article

References (97)

1. Andrews WC. The transitional years and beyond. Obstet Gynecol 1995;85:1-5.
2. Speroff L. The menopause, a signal for the future. In: Lobo RA, ed. Treatment of the postmenopausal woman: Basic and clinical aspects. New York: Raven Press, 1994:1.
3. Evans WJ, Evans MI, Hajj SN. The aging population. In: Hajj SN, Evans WJ, eds. Clinical postreproductive gynecology. East Norwalk, Connecticut. Appleton and Lange, 1993:3.
4. National Center for Health Statistics. Health, United States, 1493. Hyattsville, Maryland: Public Health Service, 1994:91.
5. Hazzard WR. Biological basis of the sex differential in longevity. J Am Geriatr Soc 1986;34:455.
6. Kannel WB. Metabolic risk factors for coronary heart disease in women. Perspective from the Framingham Study. Am Heart J 1987;114:413.
7. United States Bureau of the Census. Projections of the populations of the United States: 1977 to 2050. Curr Pop Rep Service, p 25, No 704.
8. Fries HF. Aging, natural death and the compression of morbidity. N Engt J Med 1980;303:130.
9. Fries HF, Green LW, Levine S. Health preservation and the compression of mortality. Lancet 1989;i:481.
10. McKinley SM, Bigano NL, McKinky JB. Smoking and age at menopause. Ann Intern Med 1985;103:350.
11. McKinley WM, Brambilla DJ, Posner JG. The normal menopausal transition. Maturitas 1992;14:102.
12. Sherman BM, West JH, Korenman SG. The menopausal transition; analysis of LH, FSH, estradiol and progesterone concentrations during menstrual cycles of older women. J Clin Endocrinol Metab 1976;42:629-36.
13. Chakravarti S, Collins WP, Forcast JD, et al. Relation between plasma hormone profiles, symptoms and response to oestrogen treatment in women approaching the menopause. Br Med I 1979;1:983-5.
14. Longcope C, Franz C, Morello C, et al. Steroid and gonadotropin levels in women during the perimenopausal years. Maturitas 1986;8:189-96.
15. Judd HL, Judd GE, Lucas WE, et al. Endocrine function of the postmenopausal ovary. Concentrations of androgens and estrogens in ovarian and peripheral blood. J Clin Endocrinol Metab 1974;39:1020-4.
16. Purifoy FE, Kooprano LH, Tatum RW. Steroid hormones and aging: Free testosterone, testosterone and androstenedione in normal females age 20-87 years. Hum Biol 1980;52:181-91.
17. Frumar A, Meldrum D, Geola F, et al. Relationship of fasting urinary calcium to circulating estrogen and body weight in post-menopausal women. J Clin Endocrinol Metab 1980;50:70-5.
18. Longcope C. Adrenal and gonadal estrogen secretion in normal females. J Clin Endocrinol Metab 1986;65:213-28.
19. Yen SSC. The biology of menopause. J Reprod Med 1977;18:287-96.
20. Treolar AF. Menstrual cyclicity and the premenopause. Maturitas 1981;3:249-64.
21. Bengtsson C, Lindquist O, Redvall I. Is the menopausal age rapidly changing? Maturitas 1979;1:159-64.
22. Kronenberg F. Hot flashes. In: Lobo RA, ed. Treatment of the postmenopausal woman: Basic and clinical aspects. New York: Raven Press, 1994:97-117.
23. Aksel S, Schomberg DW, Tyrey L, Hammond CB. Vasomotor symptoms, serum estrogens and gonadotropin levels in surgical menopause. Am J Obstet Gynecol 1976;126:165-9.
24. Silva NL, Boulant JA. Effects of testosterone, estradiol and temperature on neurons in preoptic tissue slices. Am J Physiol 1986;250: R625-32.
25. Israel SL, Schneller O. The thermogenic property of progesterone. Fertil Steril 1950;1:53-64.
26. Altura BM. Sex as a factor influencing the responsiveness of arterioles to catecholamines. Eur J Pharmacol 1972;20:261-5.
27. Casper RJ, Yen SSC, Wilhem MM. Menopausal flushes: A neuroendocrine link with pulsatile LH secretion. Science 1979;205:823-5.
28. Tataryn IV, Meldrum DR, Lu KH, et al. LH, FSH and skin temperature during menopausal hot flush. J Clin Endocrinol Metab 1979;49:1952-4.
29. Mulley G, Mitchell JRA, Tattersall RB. Hot flushes after hypophysectomy. Br Med J 1977;2:1062.
30. DeFazio J, Meldrum DR, Laufer L, et al. Induction of hot flushes in premenopausal women treated with a long-acting GnRH agonist. J Clin Endocrinol Metab 1983;56:445-8.
31. Erlik Y, Tataryn IV, Meldrum DR, et al. Association of waking episodes with menopausal hot flushes. JAMA 1981;245:1741-4.
32. Coope J, Thomsen JM, Pollen L. Effects of "natural estrogen" replacement therapy on menopausal symptoms and blood clotting. Br Med J 1975;4:139-43.
33. Steingold KA. Treatment of hot flashes with estradiol administration. J Clin Endocrinol Metab 1985;61:627-32.
34. Haas S, Walsh B, Evans S, et al. The effect of transdermal estrogen on hormone and metabolic dynamics over a six-week period. Obstet Gynecol 1988;71:671-6.
35. Schiff I, Tulchinsky D, Crand D, Ryan KJ. Oral medroxyprogesterone in the treatment of postmenopausal symptoms. JAMA 1980;244:1443-5.
36. Clayden JR, Bell JW, Pollard P. Menopausal flushing, double blind trial of nonhormonal medication. Br Med J 1974;1:409-12.
37. Coope J, Williams S, Patterson JS. A study of the effectiveness of propranolol in menopausal hot flushes. Br J Obstet Gynaecol 1978;85:472-5.
38. Lebherz TB, French L. Nonhormonal treatment of the menopausal syndrome. Obstet Gynecol 1969;33:795-9.
39. Oriloa HA, Maibach HI. Vulvar transdermal water loss (TEWL) decay curves. Effect of occlusion, delipidation, and age. Acta Derm Venereol (Stockh) 1989;69:461-5.
40. Bachman GA, Lieblum SR, Grill J. Brief sexual inquiry in a gynecologic practice. Obstet Gynecol 1989;73:425-7.
41. Bhatia NN, Bergman A, Karram MM. Effects of estrogen on urethral function in women with urinary incontinence. Am J Obstet Gynecol 1989;160:176-81.
42. Wilson PD, Faragher B, Butler B, et al. Treatment with oral piperazine oestrone sulphate for genuine stress urinary incontinence in postmenopausal women. Br J Obstet Gynaecol 1987;94: 568.
43. Montgomery JC, Bricart M, Tapp A, et al. Effect of oestrogen and testosterone on psychological disorders in the climacteric. Lancet 1987;i:297-9.
44. Sherwin RB, Gelfand MM. Sex steroids and affect in the surgical menopause: A double-blind, crossover study. Psychoneuroendocrinology 1985;10:325-35.
45. Hammond CB. The climacteric. In: Scott JR, DiSaia PJ, Hammond CB, Spellacy WN, eds. Danforth's obstetrics and gynecology. 7th ed. Philadelphia: Lippincott, 1994:777.
46. Sherwin BB, Karper D. Estrogen and memory in postmenopausal women with Alzheimer's disease. Presented at the Third Annual Meeting of the North American Menopause Society, Cleveland, Ohio, September 17, 1992.
47. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. Psychosom Med 1987;49:397-404.
48. Hui SL, Slemenda CW, Johnson CC. Baseline measurement of bone mass predicts fracture in white women. Ann Intern Med 1989;111: 355-61.
49. Ross PD, Davis JW, Epstein RS, et al. Preexisting fractures and bone mass predict vertebral fracture incidence in women. Arch Intern Med 1991;114:919-23.
50. Slemenda CW, Johnston CC. Epidemiology of osteoporosis. In: Lobo RA, ed. Treatment of postmenopausal women: Basic and clinical aspects. New York: Raven Press, 1993:161-8.
51. Recker RR, Davies MM, et al. Bone gain in young adult women. JAMA 1992;268:2403-8.
52. Frost HM. The skeletal intermediary organization. A. Synthesis. In: Peck WA, ed. Bone and Mineral Research. 3rd ed. Amsterdam: Elsevier, 1985:49-107.
53. Smith DM, Nance WC, Kang KW, et al. Genetic factors in determining bone mass. J Clin Invest 1973;52:2800-8.
54. Slemenda CW, Christian JC, Reed T. et al. Long-term bone loss in man: Effects of genetic and environmental factors. Ann Intern Med 1992;117:286-91.
55. Heaney RP, Recker RR, Saville PD. Menopausal changes in calcium balance performance. J Lab Clin Med 1978;92:953-63.
56. Riggs BL. Treatment of osteoporosis with sodium fluoride: An appraisal. Bone Miner Res 1983;2:366-93.
57. Overgaard K, Riis BJ, Christiansen C, et al. Nasal calcitonin for treatment of established osteoporosis. Clin Endocrinol (Oxf) 1989; 30:435-42.
58. Storm TM, Thamsborg G, Steinicke T, et al. Effect of intermittent cyclical etidronate therapy on bone mass and failure rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265-71.
59. Christiansen C, Christiansen S, McNair P, et al. Prevention of early postmenopausal bone loss. Controlled 2-year study in 315 normal females. Eur J Clin Invest 1980;10:273-9.
60. Riis BJ, Thomsen K, Strom V, et al. The effect of percutaneous estradiol and natural progesterone on postmenopausal bone loss. Am J Obstet Gynecol 1987;156:61-3.
61. Lindsay R, Hart DM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984;63:759.
62. Monthly Vital Statistics Report, 1992.
63. National Institutes of Health. Chartbook on cardiovascular, lung, and blood diseases. Washington, DC: United States Department of Health and Human Services, May 1992.
64. Bush TL. The epidemiology of cardiovascular disease in postmenopausal women. Ann NY Acad Sci 1990;592:263-71.
65. Kalin MF, Zumoff B. Sex hormones and coronary disease: A review of the clinical studies. Steroids 1990;55:330-52.
66. Advance report of final monthly statistics. 1989 Monthly Vital Stat Rep 1992;40(suppl 2):1-47.
67. Miller VT. Dyslipoproteinemia in women: Special considerations. Endocrinol Metab Clin North Am 1990;19:381-98.
68. Manson JE, Colditz GA, Stampler MJ, et al. A prospective study of obesity and risk of coronary heart disease in women. N Engl J Med 1990;322:882-9.
69. Zamboni M, Arnellini F, Milan MP, et al. Body fat distribution in pre-and postmenopausal women: Metabolic and anthropometric variables and their interrelationships. Int J Obesity 1992;16:495-504.
70. Larsson B, Bengtsson C, Bjorntop P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? Am J Epidemiol 1992;135:266-73.
71. Jacobs DR, Mebane IL, Bangdivale SI, et al. High density lipoprotein cholesterol as a predictor of cardiovascular disease mortality in men and women: The follow-up study of the Lipid Research Clinics Prevalence Study. Am J Epidemiol 1990;131:32-47.
72. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentrations and coronary heart disease in populations with low cholesterol concentrations. Br Med J 1991;303:276-82.
73. MacMahon S, Peta R, Cutler J, et al. Blood pressure, stroke and coronary heart disease. Lancet 1990;335:765-74.
74. Kennel WB, Wilson PWF, Zhang TJ. The epidemiology of impaired glucose tolerance and hypertension. Am Heart J 1991;121:1268-73.
75. Goradish GI, Utian WH. Epidemiology and high risk factors of cardiovascular disease in postmenopausal women. In: Lobo RA, ed. Treatment of postmenopausal women: Basic and clinical aspects. New York: Raven Press, 1994:199-226.
76. Ford ES, DeStafano F. Risk factors for mortality from all causes and from coronary artery disease among persons with diabetes. Am J Epidemiol 1991;133:1220-30.
77. Willett WC, Green A, Stamfer MJ, et al. Relative and absolute excessive risks of coronary heart disease among women who smoke cigarettes. N Engl J Med 1987;319:1303-9.
78. Bush TL, Comstock CW. Smoking and cardiovascular mortality in women. Am J Epidemiol 1983;118:480-8.
79. Paffenberger RS, Hide PHRT, Wing AL, et al. Physical activity, all-cause mortality and longevity of college alumni. N Engl J Med 1986;314:610-3.
80. Lobo RA, Speroff L. International Consensus Conference on post-menopausal hormone therapy and the cardiovascular system. Fertil Steril 1994;62(suppl 2):176S-9S.
81. Henderson BE. The cancer question: An overview of recent epidemiologic and retrospective data. Am J Obstet Gynecol 1989;161: 1859-64.
82. Hulka BA. Links between hormone replacement therapy and neoplasm. Fertil Steril 1994;62(suppl 2):168S-75S.
83. Spicer DV, Pike MC. Epidemiology of breast cancer. In: Lobo RA, ed. Treatment of postmenopausal women: Basic and clinical aspects. New York: Raven Press, 1994:315-24.
84. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985-90.
85. Sillero-Arenas M, Delgado Rodriguez M, Ridigues-Canteras R, et al. Menopausal hormone replacement therapy and breast cancer: A meta-analysis. Obstet Gynecol 1992;79:286-94.
86. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1991;151:67-71.
87. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016-37.
88. Bates SK. Estrogen and breast cancer. J Soc Obstet Gynecol Can 1990;12:9.
89. Armstrong BK. Oestrogen therapy after menopause - boon or bane? Med J Aust 1988;148:213.
90. Gambrell RD. Prevention of endometrial cancer with progestogens. Maturitas 1986;8:159-68.
91. Utian WH, Schiff I. North American Menopause Society-Gallup Survey on women's knowledge, information sources and attitudes to menopause and hormone replacement therapy. Menopause J NAMS 1994;1:39-48.
92. Ravniker VA. Compliance with hormone replacement therapy Are women receiving the full impact of hormone replacement therapy preventative health benefits. Women's Health Issues 1992; 2:75-82.
93. Cavley JA, Cummings SR, Black DM, et al. Prevalence and determinants of estrogen replacement therapy in elderly women. Am J Obstet Gynecol 1990;163:1438-44.
94. Rowles B. Proceedings of the Third International Symposium on Osteoporosis Consensus Development, Copenhagen, 1990.
95. Hammond CB. Women's concerns with hormone replacement therapy - compliance issues. Fertil Steril 1994;62(suppl 2):157S-60S.
96. Coope J, Marsh J. Can we improve compliance with longterm ERT? Maturitas 1992;15:151-4.
97. Thomas HT, ed. Quotable women: A collection of shared thoughts. Philadelphia: Running Press, 1989:85.